Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corporation (EXAS) delivers innovative cancer diagnostics through products like Cologuard® and Oncotype DX®. This page provides investors and healthcare professionals with essential updates on the company’s advancements in early cancer detection.
Find curated press releases and news covering financial results, regulatory milestones, product innovations, and strategic partnerships. Our repository ensures timely access to developments impacting precision oncology and noninvasive screening technologies.
Stay informed about EXAS’ role in molecular diagnostics, including updates on clinical studies, technology licensing agreements, and market expansion efforts. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Exact Sciences’ latest developments. Check back regularly for authoritative updates directly affecting the future of cancer screening and diagnostic solutions.
Exact Sciences Corp. (NASDAQ: EXAS) presented performance data for its blood-based colorectal cancer (CRC) screening test at the ESMO Congress. The test showed sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at 90.1% specificity. The study included over 3,000 blood samples, with most from the BLUE-C study.
The company aims to close the screening gap through innovation, combining a novel panel of markers. BLUE-C results are now expected in the first half of 2025, which will support an FDA submission. If approved, this test could provide another option for 60 million unscreened people in the US.
Exact Sciences also presented data on its multi-cancer early detection (MCED) blood test, showing 54.8% sensitivity at 98.5% specificity for cancers without standard screening options, and 63.7% for six aggressive cancers.
Exact Sciences Corp. (Nasdaq: EXAS), a leading cancer screening and diagnostic test provider, has announced its participation in two upcoming investor conferences. The company will be present at the Wells Fargo Healthcare Conference in Boston on September 4, 2024, with a fireside chat scheduled for 3:45 p.m. ET. Additionally, Exact Sciences will participate in the Baird Global Healthcare Conference in New York on September 11, 2024, with a fireside chat at 10:15 a.m. ET.
Investors are invited to join the webcasts of these events, which will be accessible through the investor relations section of Exact Sciences' website at www.exactsciences.com. These conferences provide an opportunity for the company to engage with investors and share insights into its operations and future prospects in the healthcare sector.
Exact Sciences Corp. (Nasdaq: EXAS) has initiated its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence study, enrolling the first patient at Baylor Scott & White Health in Texas. The study aims to enroll up to 25,000 patients aged 50-80 with no cancer history, evaluating the clinical performance and impact of MCED testing over a five-year period. Endeavor Health in Illinois will also participate, starting enrollments this fall.
The study, authorized by the FDA under an investigational device exemption, will provide insights for developing Exact Sciences' future MCED test. Participants will undergo annual MCED testing for three years, followed by two years of follow-up data collection. The test combines two high-performing biomarker classes to detect cancer early, potentially addressing the gap in existing screening programs and aligning with the U.S. government's Cancer Moonshot initiative to reduce cancer mortality by 50% over 25 years.
Exact Sciences Corp. (Nasdaq: EXAS) has shared new modeling data on the impact of their Cologuard test for colorectal cancer (CRC) screening over the past decade. The data reveals that:
- Over 16 million Cologuard screenings have been completed
- 525,000 people with advanced precancerous lesions were detected
- 80% of cancers detected were early-stage
- An estimated $22 billion in healthcare costs have been saved
The Cologuard test has contributed significantly to increasing CRC screening rates from 63% in 2015 to 72% in 2021 among Americans ages 50-75. It has also tripled screening rates for ages 45-49 from 2021 to 2023. Exact Sciences is currently awaiting FDA review for their next-generation Cologuard test, aiming to further improve CRC screening accuracy and accessibility.
TwinStrand Biosciences and Exact Sciences (Nasdaq: EXAS) have announced an exclusive license agreement for TwinStrand's Duplex Sequencing technology in the cell-free nucleic acid sequencing space. This technology enhances next-generation sequencing accuracy by up to 10,000 times, enabling detection of ultra-low frequency mutations.
The agreement grants Exact Sciences the right to use, commercialize, and sublicense the intellectual property, which includes patent portfolios from the University of Washington and the University of Texas Southwestern. Exact Sciences' rights are broadly exclusive for cell-free nucleic acid sequencing, with some non-exclusive exceptions.
This partnership aims to accelerate advancements in early cancer detection and precision oncology, potentially leading to more precise and reliable cancer diagnostic solutions for patients and healthcare providers worldwide.
Exact Sciences Corp. (EXAS) reported strong Q2 2024 results, with total revenue of $699 million, up 12% year-over-year. Screening revenue increased 15% to $532 million, while Precision Oncology revenue grew 7% to $168 million. The company screened over 1 million people with Cologuard for the first time in a quarter. Despite the revenue growth, Exact Sciences reported a net loss of $16 million, or $0.09 per share, which is an improvement from the previous year. Adjusted EBITDA rose to $110 million, with a margin of 16%. The company maintained its full-year 2024 revenue guidance and raised its adjusted EBITDA guidance midpoint by $8 million.
Imperative Care, a medical technology company focused on stroke and ischemic diseases, has announced the initial closing of an oversubscribed Series E financing led by Ally Bridge Group. The financing, which may raise up to $150 million in total, includes participation from existing and new investors. The funds will support the company's hypergrowth strategy and investment in novel technologies and clinical evidence.
Additionally, Shacey Petrovic has been appointed to the newly created position of Vice Chair of the Board of Directors. Petrovic, who joined the board in 2023, will focus on scaling strategies to bring life-changing technologies to more patients. She previously served as President and CEO of Insulet and currently sits on the boards of Exact Sciences (EXAS), Ambu A/S, and Axena Health.
Exact Sciences, a leading cancer screening and diagnostic tests provider, will release its second quarter 2024 financial results after U.S. market close on July 31, 2024.
A webcast and conference call to discuss these results is scheduled for 5 p.m. ET the same day. The webcast will be accessible on the company's website, with domestic and international dial-in options available. A replay will also be offered on the website.
Exact Sciences, a key player in cancer screening and diagnostics, announced its participation in major investor conferences this June. The company will present at the William Blair 44th Annual Growth Stock Conference in Chicago on June 4, 2024, at 1:40 p.m. ET. They will also hold a fireside chat at the Jefferies Healthcare Conference in New York on June 5, 2024, at 11:00 a.m. ET, and another at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 11, 2024, at 3:20 p.m. ET. Investors can join these events via webcast accessible through Exact Sciences' investor relations website.
Exact Sciences, a leader in cancer screening and diagnostics, will present 10 abstracts at the ASCO Annual Meeting from May 31 to June 4, 2024. Key presentations will highlight the predictive and prognostic value of the Oncotype DX Breast Recurrence Score test across diverse racial and ethnic groups. Studies confirm that the test predicts breast cancer survival and chemotherapy benefits, even in lymph node-negative patients. Additional data will showcase Exact Sciences' efforts in multi-cancer early detection (MCED) and optimized screening adherence strategies for the Cologuard test, demonstrating high adherence rates and early detection benefits. Dr. Rick Baehner emphasized the company's commitment to developing accessible, high-quality diagnostic tools to improve patient outcomes.
Presentations include data from over 171,000 patients showing that the Recurrence Score is predictive of chemotherapy benefit, particularly in non-Hispanic Black patients with higher scores. Furthermore, MCED testing showed a significant reduction in late-stage diagnoses. Real-world evidence indicates high adherence to the Cologuard test, with digital outreach enhancing screening completion rates.
